

MAXIGEN BIOTECH INC.
The 2022 Annual Shareholders' Meeting

Time: 9 a.m. on Tuesday, June 21, 2022

Place: 3F No. 88, Keji 1st Rd, Guishan District Taoyuan City

Present: The total number of shares represented by the shareholders present together with their proxies was 55,841,763 shares (554,755 shares by electronic means), representing 72.52% of the total issued shares of 76,999,235 shares of the Company. The number of shares present was in compliance as required by the Company Act.

Chairperson: Yung-Hsiang Lin Recorded by: Mei-Hua Zhao

Attendance: Independent Director Sung-Yuan Liao, Independent Director Chung-Ming Tseng, Independent Director Shih-Ming Li, Director Ching-Ting Chen, Financial and Accounting Manager Wan-Hao You, Accountant Ming-Chuan Hsu and Lawyer Yuan-Yao Jhong.

1. Call the Meeting to Order: The number of shares present exceeded the requirements of the Company Act and the Chairman called the meeting to order in accordance with the law.

2. Chairman Remarks: (skip).

3. Management Presentation

Report No.1

2021 Business Report

Explanation: (1) The 2021 Business Report is attached as Attachment 1.
(2) The Financial Statements are attached as Attachment 3.

Report No.2

2021 Audit Committee's Financial Statement Report

Explanation: The Audit Committee's Financial Statement Report is attached as Attachment 2.

Report No.3

Directors' Compensation and Employee Profit Sharing Plans

Explanation: (1) In accordance with Article 19 of the Articles of Incorporation of MBI, the proposed amount of directors' remuneration for 2021 is NT\$4,200,000 (4.81% of net income). The directors' compensation will be appropriated from the surplus in accordance with Article 4 of the Regulations Governing Directors' Remuneration adopted on July 27, 2021.
(2) In accordance with Article 19 of the Articles of Incorporation of MBI, the proposed amount of employee profit sharing for 2021 is NT\$11,288,871 (10% of net income before tax).
(3) The proposal has been approved by the Audit Committee and the Remuneration Committee, and submitted to the Board of Directors for discussion and approval.

Report No.4

Individual Director's Remuneration Report

Explanation: (1) The Individual Director's Remuneration Report is attached as Attachment 4.

4. Proposals

1. Proposed by the Board

Proposal: Adoption of the Company's 2021 Annual Business Report and Financial Statements

Explanation: (1) MBI's Financial Statements, including Consolidated Financial Statements, and Business Report, were audited by independent auditors, Ming-Chuan Hsu and Ping-Chun Chih of PwC Taiwan. Also, Financial Statements and Consolidated Financial Statements have been approved by the Boards of Directors and examined by the Audit Committee on March 21, 2022.

(2) The 2021 Business Report, Independent Auditor's Report, Financial Statements and Consolidated Financial Statements are attached as Attachment 1 and Attachment 3.

(3) Please resolve.

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 55,841,763

Voting Results (including electronic votes)	Percentage of voting rights of shareholders present at the time of voting
Approval votes: 54,789,318	98.11%
Disapproval votes: 3,246	0.00%
Invalid votes: 0	0.00%
Absentation votes/no votes: 1,049,199	1.87%

Proposal was approved as proposed.

2. Proposed by the Board

Proposal: Adoption of the Proposal for Distribution of 2021 Profits

Explanation: (1) The Company's net income for 2021 is NT\$87,667,105, plus NT\$268,960 for remeasurement of defined benefit plans, subtracting NT\$754,660 for employee stock options recognized in retained earnings, subtracting NT\$8,718,141 for legal reserve, adding NT\$25,872 for reversal of special reserve (conversion differences of financial statements of foreign operating companies), resulting in distributable earnings of NT\$78,489,136. In consideration of the Company's capital requirements for operational development, the Company intends to distribute stock dividends of NT\$76,999,230 (0.1 share per share).

(2) The Company's 2021 net income is as follows:

MAXIGEN BIOTECH INC.

Distribution of Profits

2021

Unit: NTD\$

Retained earnings at the beginning of the period		\$ 524,698
Defined benefit plan remeasurement recognized in retained earnings	268,960	
Employee stock options recognized in retained earnings	(754,660)	
Net income after tax	87,667,105	
Net income after tax for the period plus amounts included in unappropriated earnings for the year other than net income after tax for the period		87,181,405
Appropriation of statutory surplus reserve (10%)	(8,718,141)	
Reversal of special reserve in accordance with the law	25,872	
Available profits for distribution		78,489,136
Dividends distributed during the period (stock dividends)		(76,999,230)
Unallocated profits at the end of the period		\$ 2,014,604

Chairman: Yung-Hsiang Lin

Manager: Ching-Ting Chen Accounting

Manager: Yi-Huan You

- (3) After this profit distribution proposal is approved by the annual general meeting, the Chairman is authorized to set another ex-dividend date, distribution date, and other related matters.
- (4) If there is a subsequent change in the number of outstanding shares due to a change in the Company's share capital, resulting in a change in the dividend distribution rate, it is proposed that the annual general meeting will authorize the Chairman with full authority to handle the dividend distribution in accordance with the Company Act or related regulations.

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 55,841,763

Voting Results (including electronic votes)	Percentage of voting rights of shareholders present at the time of voting
Approval votes: 54,788,313	98.11%
Disapproval votes: 3,250	0.00%
Invalid votes: 0	0.00%
Absentation votes/no votes: 105,0200	1.88%

Proposal was approved as proposed.

5. Discussion

1. Proposed by the Board

Proposal: The Company proposes for a new share issue through capitalization of earnings in 2022.

- Explanation: (1) The Company is expected to issue 7,699,923 new shares with a face value of NT\$10 per share. 100 shares will be allotted at no cost per thousand shares in proportion to the shareholders' shareholding as recorded in the shareholders' register on the basis date of allotment. If the allotment of new shares is less than 1 share, the shareholder may register with the Company's stock transfer agent within 5 days from the date of cessation of transfer. Any fractional shares that are still less than one share after the consolidation will be reissued in cash at par value (calculated to the nearest dollar) and will be purchased by the Chairman in consultation with a specific person at par value.
- (2) In the event that the number of outstanding shares is affected by subsequent changes in the Company's capital stock and the shareholders' allotment and distribution rate changes, the Company intends to request the annual general meeting to authorize the Board of Directors to adjust the rate.
- (3) The rights and obligations of the new shares issued under the capital increase are the same as those of the common shares issued. If changes are required by the competent authorities or in response to actual circumstances, it is intended that the annual general meeting will authorize the Board of Directors to handle relevant matters with full authority.

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 55,841,763

Voting Results (including electronic votes)	Percentage of voting rights of shareholders present at the time of voting
Approval votes: 54,786,265	98.10%
Disapproval votes: 6,299	0.01%
Invalid votes: 0	0.00%
Absentation votes/no votes: 1,049,199	1.87%

Proposal was approved as proposed.

2. Proposed by the Board

Proposal: Amendments to the Company's Articles of Incorporation.

- Explanation: (1) In order to meet the Company's business development, it is proposed to amend some provisions of the Articles of Incorporation.
- (2) The Comparison of Amended Provisions is attached as Attachment 5.

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 55,841,763

Voting Results (including electronic votes)	Percentage of voting rights of shareholders present at the time of voting
Approval vote: 54,788,254	98.11%
Disapproval votes: 4,308	0.00%
Invalid votes: 0	0.00%
Absentation votes/no votes: 1,049,201	1.87%

Proposal was approved as proposed.

3. Proposed by the Board

Proposal: Amendments to the Company's Operational Procedures for Acquisition or Disposal of Assets.

Explanation: (1) In accordance with the Financial Supervisory Commission's Order No. 1110380465 dated January 28, 2022 and operational requirements, it is proposed to amend some provisions of the Procedures for Acquisition and Disposal of Assets.

(2) The Comparison of Amended Provisions is attached as Attachment 7.

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 55,841,763

Voting Results (including electronic votes)	Percentage of voting rights of shareholders present at the time of voting
Approval votes: 54,788,256	98.11%
Disapproval votes: 4,308	0.00%
Invalid votes: 0	0.00%
Absentation votes/no votes: 1,049,199	1.87%

Proposal was approved as proposed.

6. Election

1. Proposed by the Board

Proposal: Election of two additional directors

Explanation: (1) In order to meet the Company's operational requirements, it is proposed to elect two additional directors. The election of additional directors was conducted in accordance with the Company's Articles of Incorporation and relevant laws and regulations.

(2) The new directors are intended to take office upon their election at the annual shareholders' meeting. The term of office is the same as the original directors and independent directors.

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 111,683,526

No.	Name of Elected Person	Voting Results (including electronic votes)	Note
1	TCI Co., Ltd. Representative Tsong-Jieh Chiou	55,000,826	Elected as director
2	Formosa Biomedical Technology Corp. Representative Shih-Ming Lai	54,525,599	Elected as director

Proposal was approved as proposed.

7. Other Proposals

1. Proposed by the Board

Proposal: Removal of non-competition restrictions for new directors and their representatives.

Explanation: (1) In accordance with Article 209(1) of the Company Act, a director who performs acts for himself/herself or for others that fall within the scope of the Company's business shall explain the material content of his/her acts to the annual general meeting and obtain their approval.

(2) In the event that a director acts as a director for himself/herself or for another person who operates a company with the same or similar scope of business as the Company and serves as a director, without prejudice to the interests of the company. It is proposed to request the annual general to agree to remove the non-competition restrictions for new directors and their representatives.

(3) In order to facilitate shareholders to exercise their voting rights electronically, hereby release the list of director candidates for directorship from non-competition restrictions. The details of the removal are attached as Attachment 8.

Name	Removal of non-competition restrictions
TCI Co., Ltd. Institutional Director Representative Tsong-Jieh Chiou	TCI Co., Ltd. Customer Successful Manager
Formosa Biomedical Technology Corp. Institutional Director Representative Shih-Ming Lai	Deputy Director of Medical Business Development Center, Formosa Plastics Group General Administration Office

Resolution: The voting results on this proposal are as follows

Number of voting rights of shareholders present at the time of voting: 55,841,763

Voting Results (including electronic votes)	Percentage of voting rights of shareholders present at the time of voting
Approval votes: 54,774,122	98.08%
Disapproval votes: 15,231	0.02%
Invalid votes: 0	0.00%
Absentation votes/no votes: 1,052,410	1.88%

Proposal was approved as proposed.

8. Provisional Motion: None

9. Meeting Adjourned (09:33 A.M.)

Maxigen Biotech Inc.

2021 Business Report

1. Business scope

The core technology of Hekang Biotechnology Co., Ltd. is the application of biopolymer materials such as collagen and hyaluronic acid (also known as hyaluronic acid) in the two business divisions of biological medical materials and medical beauty care products. After years of efforts, the biomedical division of Hekang company has successfully developed 21 high-level implantable medical materials for application in orthopedics, dentistry, ophthalmology, dermatology, plastic surgery and other fields, and obtained 56 product licenses including Taiwan, the European Union, the United States, Singapore, Indonesia, Malaysia and China. The maintenance products division focuses on the development business of large maintenance products manufacturers at home and abroad, developing exclusive formula, coating process technology and micro penetration technology, so as to improve the competitive advantage of the development business of maintenance products.

After joining Dajiang group in July 2021, in order to concentrate more resources, Hekang biotechnology will adjust the cause of maintenance products. Tainan health care products factory will be transformed into a Peifu pet factory, and the OEM orders for health care products will be transferred to Dajiang biomedical S11 green energy facial mask factory. In addition to medical materials and maintenance products, R & D will also develop more diversified raw materials Maxi collagen, Maxi HA and private brand health food.

2. Operating results in 2021

The company's net operating income in 2021 was NT \$511976 thousand, an increase of 54285 thousand or 12% compared with 457691 thousand in 2020. Among them, the revenue of biomedical products division was 414874 thousand, an increase of 101324 thousand over 313550 thousand in 2020, an increase of 32.3%, mainly due to the help of orders for joint injections and collagen medical materials. In addition, the revenue of the maintenance products division was 97102 thousand, a decrease of 47039 thousand and a decline of 32.6% compared with 144141 thousand yuan in 109, mainly due to the reduction in the demand of OEM customers caused by the epidemic. In the year of 2021, the operating expense rate remained 33%, mainly due to the R & D expenses for the development of high-grade composite bone materials containing bone growth promoting substances. The net profit after tax in the year of 2021 increased by 38.5% compared with that in the year of 2020.

3. Research and development

The company's core technology is to develop implantable biomedical products based on collagen and hyaluronic acid (also known as hyaluronic acid) to repair or replace human defective tissues. R & D achievements in the year of 2021: a total of 7 new listing licenses for self owned products and 3 renewal licenses for key products were completed. The description is as follows:

- February 2021: artiaid intra-articular injection and artiaid plus intra-articular injection obtained the marketing license in Ukraine.

- March 2021: formaaid collagen membrane obtained the import license from Vietnam.
- August 2021: formaaid collagen membrane obtained the listing license in Malaysia.
- September 2021: healiaid collagen wound dressing obtained the import license from Myanmar.
- September 2021: bestaid collagen bone graft obtained the listing license in Malaysia.
- October 2021: attrax scaffold obtained the extension of the listing license in Taiwan.
- June 2021: the renewal of China's listing license of foramic bone substitute granules was completed.
- July 2021: formaderm dermal filler injection completed the renewal of the listing license in China.
- November 2021: viscaid ophthalmic viscoelastic completed the renewal of the listing license in China.

In the product development of Xinchuang biomedical materials, the company developed the "high-level implantable composite bone materials development plan containing osteogenic substances". Since August 2018, the company has received a subsidy of NT \$43.2 million through the a + enterprise innovation research and development quenching plan (forward-looking technology research and development plan) of the Ministry of economy. It is expected to complete various preclinical tests in 2022.

In addition, in order to improve the competitiveness of products, the company has increased the investment in clinical trials year by year. Two clinical trials were completed in 2021 years, and another one is under implementation. The description is as follows:

- (1) "Study on the safety and efficacy of hyaluronic acid injection in patients with carpometacarpal arthritis" was carried out in Yida hospital and has been completed.
- (2) "Post marketing clinical trial of fumeideng (containing lidocaine) dermal filler" was carried out in the Third Military General Hospital and National Taiwan University Hospital, and has been completed.
- (3) "Pre marketing clinical trial of Fu Liang skin filler" is being implemented in China.

The research and development achievements of the maintenance products division in the year of 2021 are as follows:

(1) Sunscreen formula platform

Nine sunscreen formulations have been successfully developed, which have different sunscreen efficacy and texture characteristics, allowing customers to have diversified choices and shorten the time for drug certificate examination.

(2) Micro molecular formula platform

Five kinds of micro molecular formulas have been successfully developed, including moisturizing, whitening and anti-aging functions. They are suitable for liquid and essence formulations, supplemented with other specified ingredients to increase the selling points of customers' commodity marketing demands.

(3) Freeze drying technology platform

The freeze-drying technology of biomedicine is applied to the development of new cloth film materials, so that the combination of carrier and formula can be more diversified and sustainable, and the formula and conditions are optimized.

After years of efforts, the company's biomedical division and maintenance products division have established a solid foundation, and will continue to deepen the core competence of innovative R & D and develop innovative products in the future. Make effective products for global customers, and assist existing customers to globalize and market their products all over the world. Strengthen the ability of marketing business development and continue to create profitable growth. Adhering to the demand of human health, the company will create disease solutions with hyaluronic acid and collagen to join and improve human life.

Chairman: Yung-Hsiang Lin

Manager: Ching-Ting Chen

Accounting Manager: I-Hua Yu

Audit Committee Report

The Board of Directors has prepared and submitted the 2021 business report, financial statements, and earnings distribution proposal, of which the financial statements have been audited by CPAs of PwC Taiwan, Ming-Chuan Hsu and Ping-Chun Chih. These have been reviewed by the Audit Committee as correctly portraying the Company's business activities. In accordance with Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, this report is submitted for shareholders' examination.

To

2022 Annual Shareholders' Meeting

Maxigen Biotech Inc.

Audit Committee convener: Sung-Yuan Liao

March 21, 2022

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of Maxigen Biotech Inc.

Opinion

We have audited the accompanying consolidated balance sheet of Maxigen Biotech Inc. and subsidiaries (the “Group”) as at December 31, 2021, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2021, and its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audit in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and generally accepted auditing standards in the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2021 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Group's 2021 consolidated financial statements are stated as follows:

Existence and occurrence of top ten customers

Description

The Group is primarily engaged in the production and sale of biomedical materials and care products. Except for Taiwan, the Group's customers are spread in America, Europe, Mainland China and South East Asia, the transaction terms for each customer were not the same, the audit procedures required more human resource, and the revenue from the Group's top 10 customers presented significant proportion in the operating revenue of consolidated financial statements. Thus, we considered existence and occurrence of top 10 sales customers as a key audit matter.

Please refer to Note 4(25) for accounting policies on revenue recognition and Note 6(17) for details of sales revenue.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

- A. Understood and tested the internal control of sales revenue recognition of top 10 customers, and tested the effectiveness of internal control in relation to the sales revenue.
- B. Sampled and verified the sales orders and delivery documents of top 10 customers, and confirmed that the sales revenue transaction actually occurred.
- C. Sampled and verified the sales returns and discounts of top 10 customers, and confirmed the existence of sales revenue recognition.

Other matter – Reference to the audits of other auditors

The consolidated financial statements of the Group for the year ended December 31, 2020, were audited by other auditors who expressed an unmodified opinion on those statements dated March 22, 2021.

Other matter – Parent company only financial statements

We have audited and expressed an unqualified opinion on the parent company only financial statements of the Group as at and for the years ended December 31, 2021 and 2020.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the generally accepted auditing standards in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the generally accepted auditing standards in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk

of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters

that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Hsu, Ming-Chuan

Chih, Ping-Chiun

For and on behalf of PricewaterhouseCoopers, Taiwan
March 21, 2022

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

MAXIGEN BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars))

Assets	Notes	December 31, 2021		December 31, 2020		
		AMOUNT	%	AMOUNT	%	
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 513,305	41	\$ 209,762	22
1136	Financial assets at amortised cost— current	6(2) and 8	26,872	2	13,131	1
1150	Notes receivable, net	6(3)	47,629	4	35,564	4
1170	Accounts receivable, net	6(3)	45,625	4	52,902	5
1180	Accounts receivable due from related parties, net	7	16,692	1	6,443	1
1200	Other receivables		4,455	-	7,024	1
1210	Other receivables due from related parties	7	5	-	-	-
130X	Inventories	6(4)	78,954	6	86,984	9
1410	Prepayments	6(5)	49,760	4	19,945	2
1470	Other current assets		256	-	303	-
11XX	Total current assets		<u>783,553</u>	<u>62</u>	<u>432,058</u>	<u>45</u>
Non-current assets						
1600	Property, plant and equipment	6(6)	456,062	36	469,598	49
1755	Right-of-use assets	6(7)	9,391	1	11,919	1
1760	Investment property, net	6(8)	8,859	1	8,890	1
1780	Intangible assets	6(9)	1,830	-	1,673	-
1840	Deferred tax assets		378	-	1,069	-
1900	Other non-current assets	6(5)	5,111	-	31,263	4
15XX	Total non-current assets		<u>481,631</u>	<u>38</u>	<u>524,412</u>	<u>55</u>
1XXX	Total assets		<u>\$ 1,265,184</u>	<u>100</u>	<u>\$ 956,470</u>	<u>100</u>

(Continued)

MAXIGEN BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars))

	Liabilities and Equity	Notes	December 31, 2021		December 31, 2020	
			AMOUNT	%	AMOUNT	%
Current liabilities						
2130	Current contract liabilities	6(17)	\$ 11,126	1	\$ 3,763	-
2150	Notes payable		100	-	-	-
2170	Accounts payable		16,772	1	27,905	3
2180	Accounts payable to related parties	7	23,281	2	5,096	1
2200	Other payables	6(10)	53,070	4	38,581	4
2220	Other payables to related parties	7	54	-	-	-
2230	Current tax liabilities		9,281	1	8,692	1
2280	Lease liabilities - current	6(7)	2,362	-	2,493	-
2399	Other current liabilities, others		22	-	54	-
21XX	Total current liabilities		<u>116,068</u>	<u>9</u>	<u>86,584</u>	<u>9</u>
Non-current liabilities						
2580	Lease liabilities - non-current	6(7)	7,278	1	9,640	1
2600	Other non-current liabilities		120	-	19	-
25XX	Total non-current liabilities		<u>7,398</u>	<u>1</u>	<u>9,659</u>	<u>1</u>
2XXX	Total liabilities		<u>123,466</u>	<u>10</u>	<u>96,243</u>	<u>10</u>
Equity attributable to owners of the parent						
Share capital						
3110	Ordinary share	6(13)	769,992	61	694,650	73
Capital surplus						
3200	Capital surplus	6(13)	264,392	21	89,181	9
Retained earnings						
3310	Legal surplus	6(14)	19,604	1	13,289	1
3320	Special reserve		2,985	-	2,931	-
3350	Undistributed surplus earnings		87,706	7	63,161	7
Other equity interest						
3400	Other equity interest	6(16)	(2,961)	-	(2,985)	-
31XX	Total equity attributable to owners of parent		<u>1,141,718</u>	<u>90</u>	<u>860,227</u>	<u>90</u>
3XXX	Total equity		<u>1,141,718</u>	<u>90</u>	<u>860,227</u>	<u>90</u>
Significant contingent liabilities and unrecognised contract commitments						
Significant events after the balance sheet date						
3X2X	Total liabilities and equity		<u>\$ 1,265,184</u>	<u>100</u>	<u>\$ 956,470</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

MAXIGEN BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars, except for earnings per share)

Items	Notes	Year ended December 31			
		2021		2020	
		AMOUNT	%	AMOUNT	%
4000 Operating revenue	6(17)(19)	\$ 511,976	100	\$ 457,691	100
5000 Operating costs	6(4)(11)(21)	(250,949)	(49)	(243,171)	(53)
5900 Gross profit		<u>261,027</u>	<u>51</u>	<u>214,520</u>	<u>47</u>
Operating expenses	6(11)(21)(22)				
6100 Selling expenses		(39,533)	(8)	(34,180)	(8)
6200 General and administrative expenses		(52,842)	(10)	(50,182)	(11)
6300 Research and development expenses		(75,681)	(15)	(69,150)	(15)
6450 Expected credit impairment (loss) gain		(3,024)	-	97	-
6000 Total operating expenses		<u>(171,080)</u>	<u>(33)</u>	<u>(153,415)</u>	<u>(34)</u>
6900 Operating profit		<u>89,947</u>	<u>18</u>	<u>61,105</u>	<u>13</u>
Non-operating income and expenses					
7100 Interest income	6(18)	481	-	775	-
7010 Other income	6(19)	11,454	2	23,172	5
7020 Other gains and losses	6(20)	(4,220)	(1)	(8,066)	(1)
7050 Finance costs	6(21)	(196)	-	(250)	-
7000 Total non-operating income and expenses		<u>7,519</u>	<u>1</u>	<u>15,631</u>	<u>4</u>
7900 Profit before income tax		<u>97,466</u>	<u>19</u>	<u>76,736</u>	<u>17</u>
7950 Income tax expense	6(22)	(9,799)	(2)	(13,425)	(3)
8200 Profit for the year		<u>\$ 87,667</u>	<u>17</u>	<u>\$ 63,311</u>	<u>14</u>
Other comprehensive income					
8311 Gains (losses) on remeasurements of defined benefit plans		\$ 269	-	(\$ 164)	-
Components of other comprehensive income that will be reclassified to profit or loss					
8361 Exchange differences on translation	6(16)	24	-	(54)	-
8300 Other comprehensive income		<u>\$ 293</u>	<u>-</u>	<u>(\$ 218)</u>	<u>-</u>
8500 Total comprehensive income for the year		<u>\$ 87,960</u>	<u>17</u>	<u>\$ 63,093</u>	<u>14</u>
Profit attributable to:					
8610 Owners of the parent		\$ 87,667	17	\$ 63,311	14
8620 Non-controlling interest		-	-	-	-
		<u>\$ 87,667</u>	<u>17</u>	<u>\$ 63,311</u>	<u>14</u>
Comprehensive income attributable to:					
8710 Owners of the parent		\$ 87,960	17	\$ 63,093	14
8720 Non-controlling interest		-	-	-	-
		<u>\$ 87,960</u>	<u>17</u>	<u>\$ 63,093</u>	<u>14</u>
Earnings per share					
9750 Basic earnings per share		\$ 1.21		\$ 0.91	
9850 Diluted earnings per share		\$ 1.20		\$ 0.91	

The accompanying notes are an integral part of these consolidated financial statements.

MAXIGEN BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Equity attributable to owners of the parent							
	Notes	Ordinary share	Capital surplus	Retained Earnings			Exchange differences on translation	Total equity
Legal surplus				Special reserve	Undistributed surplus earnings			
<u>Year ended December 31, 2020</u>								
Balance at January 1, 2020		\$ 694,650	\$ 89,181	\$ 7,284	\$ 3,078	\$ 60,055	(\$ 2,931)	\$ 851,317
Profit for the year		-	-	-	-	63,311	-	63,311
Other comprehensive loss for the year	6(16)	-	-	-	-	(164)	(54)	(218)
Total comprehensive income for the year		-	-	-	-	63,147	(54)	63,093
Appropriation and distribution of retained earnings for 2019:								
Legal reserve appropriated		-	-	6,005	-	(6,005)	-	-
Reversal of special reserve		-	-	-	(147)	147	-	-
Cash dividends paid		-	-	-	-	(54,183)	-	(54,183)
Balance at December 31, 2020		<u>\$ 694,650</u>	<u>\$ 89,181</u>	<u>\$ 13,289</u>	<u>\$ 2,931</u>	<u>\$ 63,161</u>	<u>(\$ 2,985)</u>	<u>\$ 860,227</u>

(Continued)

MAXIGEN BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Equity attributable to owners of the parent							
	Notes	Retained Earnings					Exchange differences on translation	Total equity
		Ordinary share	Capital surplus	Legal surplus	Special reserve	Undistributed surplus earnings		
<u>Year ended December 31, 2021</u>								
Balance at January 1, 2021		\$ 694,650	\$ 89,181	\$ 13,289	\$ 2,931	\$ 63,161	(\$ 2,985)	\$ 860,227
Profit for the year		-	-	-	-	87,667	-	87,667
Other comprehensive loss for the year	6(16)	-	-	-	-	269	24	293
Total consolidated profit for the year		-	-	-	-	87,936	24	87,960
Appropriation and distribution of retained earnings for 2020:								
Legal reserve appropriated		-	-	6,315	-	(6,315)	-	-
Special reserve appropriated		-	-	-	54	(54)	-	-
Cash dividends paid		-	-	-	-	(56,267)	-	(56,267)
Recognition of share-based payment	6(12)	-	3,203	-	-	(755)	-	2,448
Cash capital increase	6(13)	75,342	172,008	-	-	-	-	247,350
Balance at December 31, 2021		<u>\$ 769,992</u>	<u>\$ 264,392</u>	<u>\$ 19,604</u>	<u>\$ 2,985</u>	<u>\$ 87,706</u>	<u>(\$ 2,961)</u>	<u>\$1,141,718</u>

The accompanying notes are an integral part of these consolidated financial statements.

MAXIGEN BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		\$ 97,466	\$ 76,736
Adjustments			
Adjustments to reconcile profit (loss)			
Expected credit impairment loss	12(2)	3,024	(97)
Depreciation	6(6)(7)(21)	31,870	32,030
Amortisation	6(9)(22)	1,031	1,162
Interest income	6(18)	(481)	(775)
Interest expense	6(21)	196	250
Compensation cost arising from employee stock options	6(15)	2,448	-
Changes in operating assets and liabilities			
Changes in operating assets			
Notes receivable	(12,065)	(11,047)
Accounts receivable		4,253	5,430
Accounts receivable - related parties	(10,249)	8,653
Other receivables		2,569	1,279
Other receivables due from related parties	(5)	-
Inventories		8,030	1,131
Prepayments	(29,815)	(9,517)
Other current assets		47	2,398
Changes in operating liabilities			
Contract liabilities - current		7,363	(3,960)
Notes payable		100	(50)
Accounts payable	(11,133)	1,811
Accounts payable to related parties		18,185	(2,729)
Other payables		12,971	(2,300)
Other payables to related parties		54	-
Other current liabilities	(32)	(1,250)
Cash inflow generated from operations		125,827	99,155
Interest received		481	840
Interest paid	(196)	(8,831)
Income tax paid	(8,519)	(16,601)
Net cash flows from operating activities		117,593	74,563
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of property, plant and equipment	6(6)	(14,258)	(10,739)
Acquisition of intangible assets	6(9)	(1,188)	(599)
(Increase) decrease in other non-current assets		26,412	(1,618)
(Increase) decrease in financial assets at amortised cost		(13,741)	151,918
Net cash flows (used in) from investing activities		(2,775)	138,962
CASH FLOWS FROM FINANCING ACTIVITIES			
(Decrease) increase in guarantee deposits		101	(70)
Lease liabilities paid	6(7)	(2,493)	(2,558)
Repayment of preferred stock liabilities		-	(214,539)
Proceeds from issuance of common stock		247,350	-
Cash dividends paid	(56,267)	(54,183)
Net cash flows from (used in) financing activities		188,691	(271,350)
Effects due to changes in exchange rate		34	(56)
Net increase (decrease) in cash and cash equivalents		303,543	(57,881)
Cash and cash equivalents at beginning of year	6(1)	209,762	267,643
Cash and cash equivalents at end of year	6(1)	\$ 513,305	\$ 209,762

The accompanying notes are an integral part of these consolidated financial statements.

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of Maxigen Biotech Inc.

Opinion

We have audited the accompanying parent company only balance sheets of Maxigen Biotech Inc., Ltd. (the “Company”) as at December 31, 2021 and 2020, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the parent company only financial position of Maxigen Biotech Inc., Ltd as at December 31, 2021 and 2020, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers.”

Basis for opinion

We conducted our audits in accordance with the “Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants” and generally accepted auditing standards in the Republic of China. Our responsibilities under those standards are further described in the *Auditor’s Responsibilities for the Audit of the parent company only Financial Statements* section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountants in the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements of the current period. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters in relation to the parent company only financial statements for the year ended December 31, 2021 are outlined as follows:

Existence and occurrence of top ten customers

Description

The Company's and its subsidiaries' (listed as investments accounted for under equity method) primarily engaged in production and sales of biomedical materials and care products. Except for Taiwan, the Company's and its subsidiaries' (listed as investments accounted for under equity method) customers spread in America, Europe, Mainland China and South East Asia, the transaction terms for each customer were not the same, the audit procedures required more human resource, and the revenue from the Company's and its subsidiaries' (listed as investments accounted for under equity method) top 10 customers presented significant proportion in the operating revenue of consolidated financial statements. Thus, we considered existence and occurrence of top 10 sales customers as a key audit matter.

Please refer to Note 4(25) for accounting policies on revenue recognition and Note 6(18) for details of sales revenue and Note 6(5) for details of investments accounted for under equity method.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

- A. Understood and tested the internal control of sales revenue recognition of top 10 customers, and tested the effectiveness of internal control in relation to the sales revenue.
- B. Sampled and verified the sales orders and delivery documents of top 10 customers, and confirmed that the sales revenue transaction actually occurred.
- C. Sampled and verified the sales returns and discounts of top 10 customers, and confirmed the existence of sales revenue recognition.

Other matter – Parent company only financial reports

The financial statements of the parent company only for the year ended December 31, 2020, were audited by other auditors who expressed an unmodified opinion on those statements dated March 22, 2021.

Responsibilities of management and those charged with governance for the parent company only financial statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company’s financial reporting process.

Auditors’ responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the generally accepted auditing standards in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the generally accepted auditing standards in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one

resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Hsu, Ming-Chuan

Chih, Ping-Chiun

For and on behalf of PricewaterhouseCoopers, Taiwan
March 21, 2022

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

Assets	Notes	December 31, 2021		December 31, 2020		
		AMOUNT	%	AMOUNT	%	
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 497,271	39	\$ 193,434	20
1136	Current financial assets at amortised cost		26,872	2	13,131	1
1150	Notes receivable, net	6(3)	47,629	4	35,564	4
1170	Accounts receivable, net	6(3)	45,625	4	46,727	5
1180	Accounts receivable due from related parties, net	7	28,311	2	24,502	2
1200	Other receivables		4,110	-	5,658	1
1210	Other receivables due from related parties	7	46	-	40	-
130X	Current inventories	6(4)	78,954	6	86,984	9
1410	Prepayments	6(6)	49,759	4	19,296	2
1470	Other current assets		184	-	419	-
11XX	Current assets		<u>778,761</u>	<u>61</u>	<u>425,755</u>	<u>44</u>
Non-current assets						
1550	Investments accounted for using equity method	6(5)	8,496	1	8,555	1
1600	Property, plant and equipment	6(7)	456,062	36	469,598	49
1755	Right-of-use assets	6(8)	9,391	1	11,753	1
1760	Investment property, net	6(9)	8,859	1	8,890	1
1780	Intangible assets	6(10)	1,830	-	1,673	-
1840	Deferred tax assets	6(25)	393	-	1,076	-
1900	Other non-current assets	6(6)(12)	5,111	-	31,237	4
15XX	Non-current assets		<u>490,142</u>	<u>39</u>	<u>532,782</u>	<u>56</u>
1XXX	Current tax assets		<u>\$ 1,268,903</u>	<u>100</u>	<u>\$ 958,537</u>	<u>100</u>

(Continued)

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity		Notes	December 31, 2021		December 31, 2020	
			AMOUNT	%	AMOUNT	%
Current liabilities						
2130	Current contract liabilities	6(18) and 7	\$ 9,822	1	\$ 2,417	-
2150	Notes payable		100	-	-	-
2170	Accounts payable		17,536	1	27,905	3
2180	Accounts payable to related parties	7	23,281	2	5,096	1
2200	Other payables	6(11)	52,610	4	38,756	4
2220	Other payables to related parties	7	54	-	-	-
2230	Current tax liabilities	6(26)	9,281	1	8,626	1
2280	Current lease liabilities		2,362	-	2,320	-
2300	Other current liabilities		21	-	11	-
21XX	Current liabilities		<u>115,067</u>	<u>9</u>	<u>85,131</u>	<u>9</u>
Non-current liabilities						
2580	Non-current lease liabilities		7,278	1	9,640	1
2600	Other non-current liabilities	6(5)	4,840	-	3,539	-
25XX	Non-current liabilities		<u>12,118</u>	<u>1</u>	<u>13,179</u>	<u>1</u>
2XXX	Liabilities		<u>127,185</u>	<u>10</u>	<u>98,310</u>	<u>10</u>
Equity						
Share capital		6(14)				
3110	Ordinary share		769,992	61	694,650	73
Capital surplus		6(17)				
3200	Capital surplus		264,392	20	89,181	9
Retained earnings		6(18)				
3310	Legal reserve		19,604	2	13,289	1
3320	Special reserve		2,985	-	2,931	-
3350	Unappropriated retained earnings		87,706	7	63,161	7
Other equity interest		6(17)				
3400	Other equity interest		(2,961)	-	(2,985)	-
3XXX	Equity		<u>1,141,718</u>	<u>90</u>	<u>860,227</u>	<u>90</u>
3X2X	Total liabilities and equity		<u>\$ 1,268,903</u>	<u>100</u>	<u>\$ 958,537</u>	<u>100</u>

The accompanying notes are an integral part of these parent company only financial statements.

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars, except earnings per share amount)

Items	Notes	Year ended December 31			
		2021		2020	
		AMOUNT	%	AMOUNT	%
4000 Sales revenue	6(18) and 7	\$ 511,304	100	\$ 455,279	100
5000 Operating costs	6(4)(14)(24)(25) and 7	(250,949)	(49)	(243,171)	(53)
5900 Net operating margin		<u>260,355</u>	<u>51</u>	<u>212,108</u>	<u>47</u>
Operating expenses	6(14)(24)(25)				
6100 Selling expenses		(39,032)	(8)	(33,550)	(8)
6200 General and administrative expenses		(52,457)	(10)	(49,731)	(11)
6300 Research and development expenses		(75,681)	(15)	(69,150)	(15)
6450 Impairment loss determined in accordance with IFRS 9		(3,024)	-	97	-
6000 Total operating expenses		<u>(170,194)</u>	<u>(33)</u>	<u>(152,334)</u>	<u>(34)</u>
6900 Operating profit		<u>90,161</u>	<u>18</u>	<u>59,774</u>	<u>13</u>
Non-operating income and expenses					
7100 Interest income		470	-	750	-
7010 Other income	6(20) and 7	11,453	2	22,990	5
7020 Other gains and losses	6(21)	(3,205)	(1)	(8,516)	(2)
7050 Finance costs	6(22)	(194)	-	(236)	-
7070 Share of (loss) profit of associates and joint ventures accounted for using equity method, net	6(5)	(1,285)	-	1,616	1
7000 Total non-operating income and expenses		<u>7,239</u>	<u>1</u>	<u>16,604</u>	<u>4</u>
7900 Profit before income tax		<u>97,400</u>	<u>19</u>	<u>76,378</u>	<u>17</u>
7950 Income tax expense	6(25)	(9,733)	(2)	(13,067)	(3)
8200 Profit for the year		<u>\$ 87,667</u>	<u>17</u>	<u>\$ 63,311</u>	<u>14</u>
Other comprehensive income					
Components of other comprehensive income that will not be reclassified to profit or loss					
8311 Gains (losses) on remeasurements of defined benefit plans		\$ 269	-	(\$ 164)	-
Components of other comprehensive income that will be reclassified to profit or loss					
8361 Financial statements translation differences of foreign operations	6(5)(17)	24	-	(54)	-
8300 Other comprehensive loss for the year		<u>\$ 293</u>	<u>-</u>	<u>(\$ 218)</u>	<u>-</u>
8500 Total comprehensive income for the year		<u>\$ 87,960</u>	<u>17</u>	<u>\$ 63,093</u>	<u>14</u>
Earnings per share (In dollars)					
9750 Basic earnings per share	6(26)	<u>\$ 1.21</u>		<u>\$ 0.91</u>	
9850 Diluted earnings per share	6(26)	<u>\$ 1.20</u>		<u>\$ 0.91</u>	

The accompanying notes are an integral part of these parent company only financial statements.

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Notes	Share capital - common stock	Capital surplus, additional paid- in capital	Retained Earnings			Financial statements translation differences of foreign operations	Total equity
				Legal reserve	Special reserve	Unappropriated retained earnings		
<u>For the year ended December 31, 2018</u>								
Balance at January 1, 2018		\$ 694,650	\$ 89,181	\$ 7,284	\$ 3,078	\$ 60,055	(\$ 2,931)	\$ 851,317
Profit for the year		-	-	-	-	63,311	-	63,311
Other comprehensive loss for the year	6(14)	-	-	-	-	(164)	(54)	(218)
Total comprehensive income (loss)		-	-	-	-	63,147	(54)	63,093
Appropriations of 2017 earnings (Note 2)								
Legal reserve		-	-	6,005	-	(6,005)	-	-
Special reserve		-	-	-	(147)	147	-	-
Cash dividends		-	-	-	-	(54,183)	-	(54,183)
Balance at December 31, 2018		\$ 694,650	\$ 89,181	\$ 13,289	\$ 2,931	\$ 63,161	(\$ 2,985)	\$ 860,227

(Continued)

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Notes	Share capital - common stock	Capital surplus, additional paid- in capital	Retained Earnings			Financial statements translation differences of foreign operations	Total equity
				Legal reserve	Special reserve	Unappropriated retained earnings		
<u>For the year ended December 31, 2019</u>								
Balance at January 1, 2019		\$ 694,650	\$ 89,181	\$ 13,289	\$ 2,931	\$ 63,161	(\$ 2,985)	\$ 860,227
Profit for the year		-	-	-	-	87,667	-	87,667
Other comprehensive loss for the year	6(17)	-	-	-	-	269	24	293
Total comprehensive income (loss)		-	-	-	-	87,936	24	87,960
Appropriations of 2018 earnings								
Legal reserve		-	-	6,315	-	(6,315)	-	-
Special reserve		-	-	-	54	(54)	-	-
Cash dividends		-	-	-	-	(56,267)	-	(56,267)
Share-based payments	6(13)(24)	-	3,203	-	-	(755)	-	2,448
Seasoned equity offering		75,342	172,008	-	-	-	-	247,350
Balance at December 31, 2019		<u>\$ 769,992</u>	<u>\$ 264,392</u>	<u>\$ 19,604</u>	<u>\$ 2,985</u>	<u>\$ 87,706</u>	<u>(\$ 2,961)</u>	<u>\$ 1,141,718</u>

The accompanying notes are an integral part of these parent company only financial statements.

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2021	2020
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Profit before tax		\$ 97,400	\$ 76,378
Adjustments			
Adjustments to reconcile profit (loss)			
Impairment loss determined in accordance with IFRS 9	6(3)	3,024	(97)
Gain on disposal of property, plant and equipment	6(21)	(295)	-
Share of profit of subsidiaries accounted for under equity method	6(5)	1,285	(1,616)
Depreciation	6(6)(7)(23)	31,705	31,753
Amortisation	6(10)(23)	1,031	1,162
Interest income	6(19)	(470)	(750)
Interest expense	6(22)	194	236
Compensation cost arising from employee stock options	6(15)	2,448	-
Changes in operating assets and liabilities			
Changes in operating assets			
Notes receivable		(12,065)	(11,047)
Accounts receivable		(1,922)	(8,695)
Accounts receivable due from related parties		(3,809)	25,427
Other receivables		1,548	2,645
Other receivables due from related parties	7	(6)	(40)
Inventories		8,030	1,131
Prepayments		(30,463)	(9,311)
Other current assets		235	386
Changes in operating liabilities			
Contract liabilities - current		7,405	(5,276)
Notes payable		100	(50)
Accounts payable		(10,369)	(5,883)
Accounts payable to related parties	7	18,185	5,096
Other payables		12,333	(2,351)
Other payables to related parties	7	54	-
Other current liabilities		10	(214,541)
Cash inflow (outflow) generated from operations		125,588	(115,443)
Interest received		470	815
Interest paid		(191)	(8,819)
Income tax paid		(8,395)	(16,230)
Net cash flows from (used in) operating activities		117,472	(139,677)

(Continued)

MAXIGEN BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2021 AND 2020
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2021	2020
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of property, plant and equipment		(\$ 14,258)	(\$ 10,739)
Proceeds from disposal of property, plant and equipment		295	-
Acquisition of intangible assets	6(10)	(1,188)	(599)
Increase in financial assets at amortised cost		(13,741)	151,918
(Increase) decrease in refundable deposits		(1,482)	10
Decrease (increase) in other non-current assets		<u>27,877</u>	<u>(1,415)</u>
Net cash flows (used in) from investing activities		<u>(2,497)</u>	<u>139,175</u>
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Repayments of principal portion of lease liabilities	6(7)	(2,320)	(2,280)
Increase (decrease) in other non-current liabilities		99	(70)
Cash dividends paid		(56,267)	(54,183)
Proceeds from issuance of shares		<u>247,350</u>	<u>-</u>
Net cash flows from (used in) financing activities		<u>188,862</u>	<u>(56,533)</u>
Net increase (decrease) in cash and cash equivalents		303,837	(57,035)
Cash and cash equivalents at beginning of year	6(1)	<u>193,434</u>	<u>250,469</u>
Cash and cash equivalents at end of year	6(1)	<u>\$ 497,271</u>	<u>\$ 193,434</u>

The accompanying notes are an integral part of these parent company only financial statements.

Maxigen Biotech Inc.
Report on the remuneration of individual directors in 2021

職稱	姓名	董事酬金								A、B、C及D等四項總額及占稅後純益之比例(註10)		兼任員工領取相關酬金								A、B、C、D、E、F及G等七項總額及占稅後純益之比例(註10)		領取來自子公司以外轉投資或母公司酬金(註11)
		報酬(A)(註2)		退職退休金(B)		董事酬勞(C)(註3)		業務執行費用(D)(註4)		本公司	財務報告內所有公司	薪資、獎金及特支費等(E)(註5)	退職退休金(F)	員工酬勞(G)(註6)				本公司	財務報告內所有公司			
		本公司	財務報告內所有公司(註7)	本公司	財務報告內所有公司(註7)	本公司	財務報告內所有公司(註7)	本公司	財務報告內所有公司(註7)					本公司	財務報告內所有公司(註7)	本公司	財務報告內所有公司(註7)			現金金額	股票金額	
董事	環宇投資(股) 代表人：徐立德	1277	1277	-	-	210	210	20	20	1.71	1.71									1.71	1.71	-
	環宇投資(股) 代表人：戴水泉					140	140	15	15	0.17	0.17									0.17	0.17	
	環宇財務顧問(股) 代表人：張昌邦					140	140	10	10	0.17	0.17									0.17	0.17	
	中加投資發展(股) 代表人：陳松青					210	210	20	20	0.26	0.26	1970	1970	77	77	532	532			3.20	3.20	
	中加投資發展(股) 代表人：李綉媛					600	600	60	60	0.75	0.75									0.75	0.75	
	大江生醫(股) 代表人：林詠翔					342	342	40	40	0.43	0.43	386	386							0.87	0.87	
	大江生醫(股) 代表人：陳敬亭					70	70	10	10	0.09	0.09	540	540	32	32	750	750			1.59	1.59	
	大江生醫(股) 代表人：黃振嘉					280	280	30	30	0.35	0.35									0.35	0.35	
	大江生醫(股) 代表人：傅珍珍					342	342	40	40	0.43	0.43									0.43	0.43	
獨立董事	鄧泗堂	269	269	-	-	210	210	65	65	0.62	0.62	-	-	-	-	-	-	-	-	0.62	0.62	-
	張立言					210	210	20	20	0.26	0.26									0.26	0.26	
	鄧世雄	319	319			210	210	50	50	0.66	0.66									0.66	0.66	
	陳昭龍	319	319			210	210	60	60	0.67	0.67									0.67	0.67	
	廖松淵					342	342	120	120	0.52	0.52									0.52	0.52	
	李世明					342	342	120	120	0.52	0.52									0.52	0.52	
	曾仲銘					342	342	120	120	0.52	0.52									0.52	0.52	

Maxigen Biotech Inc.

Articles of Incorporation" before and after the Amendment

Sequence Number of the Article	Amendment	Current Articles	Explanation
Article 2	<p>The Company's registered scope of business operations are as follows:</p> <ol style="list-style-type: none"> 1. F108031 Wholesale of Medical Devices 2. F108011 Wholesale of Traditional Chinese Medicine 3. F108021 Wholesale of Western Pharmaceutical 4. F108040 Wholesale of Cosmetics 5. IG01010 Biotechnology Services 6. C802100 Cosmetics Manufacturing 7. C801030 Precision Chemical Material Manufacturing 8. CF01011 Medical Devices Manufacturing 9. CE01030 Optical Instruments Manufacturing 10. ZZ99999 All businesses not prohibited or restricted by law, except for those subject to special approval <u>11. C802060 Animal drug manufacturing</u> <u>12. F102040 Beverage wholesale industry</u> <u>13. F102170 Food assorted goods wholesale industry</u> <u>14. F107070 Wholesale of animal drugs</u> <u>15. F203010 Food and beverage retail</u> <u>16. F207070 Animal drug retail</u> <u>17. F208031 Medical equipment retail</u> 	<p>The Company's registered scope of business operations are as follows:</p> <ol style="list-style-type: none"> 1. F108031 Wholesale of Medical Devices 2. F108011 Wholesale of Traditional Chinese Medicine 3. F108021 Wholesale of Western Pharmaceutical 4. F108040 Wholesale of Cosmetics 5. IG01010 Biotechnology Services 6. C802100 Cosmetics Manufacturing 7. C801030 Precision Chemical Material Manufacturing 8. CF01011 Medical Devices Manufacturing 9. CE01030 Optical Instruments Manufacturing 10. ZZ99999 All businesses not prohibited or restricted by law, except for those subject to special approval 	Cooperate with the company's business development
Article 21	<p>The Articles were first established on November 27, 1998.</p> <p>The first amendment was on May 2, 2000.</p> <p>The second amendment was on August 31, 2001.</p> <p>The third amendment was on July 29, 2002.</p> <p>The fourth amendment was on May 3, 2003.</p> <p>The fifth amendment was on September 25, 2003.</p> <p>The sixth amendment was on May 18, 2004.</p> <p>The seventh amendment was on June 24, 2005.</p> <p>The eighth amendment was on June 29, 2006.</p> <p>The ninth amendment was on January 19, 2007.</p> <p>The tenth amendment was on June 29, 2007.</p> <p>The eleventh amendment was on June 23, 2008.</p> <p>The twelfth amendment was on June 28, 2010.</p> <p>The thirteenth amendment was on May 25, 2011.</p> <p>The fourteenth amendment was on June 7, 2012.</p> <p>The fifteenth amendment was on June 22, 2015.</p> <p>The sixteenth amendment was on Dec. 25, 2015.</p> <p>The seventeenth amendment was on Jun. 24, 2016.</p> <p>The eighteenth amendment was on June 26, 2017.</p> <p>The nineteenth amendment was on June 26, 2018.</p> <p>The twentieth amendment was on June 26, 2019.</p> <p>The twenty-first amendment was made on Jun. 29, 2020.</p> <p>The twenty-second amendment was made on July 12, 2021.</p> <p><u>The twenty-second amendment was made on June 21, 2022.</u></p>	<p>The Articles were first established on November 27, 1998.</p> <p>The first amendment was on May 2, 2000.</p> <p>The second amendment was on August 31, 2001.</p> <p>The third amendment was on July 29, 2002.</p> <p>The fourth amendment was on May 3, 2003.</p> <p>The fifth amendment was on September 25, 2003.</p> <p>The sixth amendment was on May 18, 2004.</p> <p>The seventh amendment was on June 24, 2005.</p> <p>The eighth amendment was on June 29, 2006.</p> <p>The ninth amendment was on January 19, 2007.</p> <p>The tenth amendment was on June 29, 2007.</p> <p>The eleventh amendment was on June 23, 2008.</p> <p>The twelfth amendment was on June 28, 2010.</p> <p>The thirteenth amendment was on May 25, 2011.</p> <p>The fourteenth amendment was on June 7, 2012.</p> <p>The fifteenth amendment was on June 22, 2015.</p> <p>The sixteenth amendment was on Dec. 25, 2015.</p> <p>The seventeenth amendment was on Jun. 24, 2016.</p> <p>The eighteenth amendment was on June 26, 2017.</p> <p>The nineteenth amendment was on June 26, 2018.</p> <p>The twentieth amendment was on June 26, 2019.</p> <p>The twenty-first amendment was made on Jun. 29, 2020.</p> <p>The twenty-second amendment was made on July 12, 2021.</p>	Added the amendment date.

Maxigen Biotech Inc.

Procedures for acquisition or disposal of assets

Amendment	Current Articles	Explanation
<p>Article 5 the professional appraiser and its appraisers, accountants, lawyers or securities underwriters shall comply with the following requirements in the valuation report or the opinion of accountants, lawyers or securities underwriters obtained by this Corporation:</p> <ol style="list-style-type: none"> 1. He has not been sentenced to fixed-term imprisonment of more than one year for violating this law, the company law, the banking law, the insurance law, the financial holding company law, the business accounting law, or for fraud, breach of trust, embezzlement, forgery of documents, or for business crimes. However, this restriction shall not apply if three years have elapsed after the completion of execution, the expiration of probation or pardon. 2. Circumstances in which a party to a transaction may not be a related party or have a material relationship with the transaction party. 3. If the company should obtain the appraisal reports of two or more professional appraisers, appraisers of different specialties or appraisers shall not be related to each other or have substantial relationship with each other. <p>When issuing a valuation report or opinion, the personnel referred to in the preceding paragraph shall comply with the self-discipline norms of their trade associations and the following matters:</p> <ol style="list-style-type: none"> 1. Before undertaking a case, you should carefully evaluate your professional ability, practical experience and independence. 2. When the case or operation report is issued, it shall be properly implemented according to the planning or operation report; The procedures, information and conclusions collected will be detailed in the case working paper. 3. The appropriateness and rationality of the data sources, parameters and information used shall be evaluated item by item as the basis for issuing the valuation report or opinion. 4. The declaration shall include the professionalism and independence of relevant personnel, the appropriateness and reasonableness of the information used in the evaluation, and compliance with relevant laws and regulations. 	<p>Article 5 the professional appraiser and its appraisers, accountants, lawyers or securities underwriters shall comply with the following requirements in the valuation report or the opinion of accountants, lawyers or securities underwriters obtained by this Corporation:</p> <ol style="list-style-type: none"> 1. He has not been sentenced to fixed-term imprisonment of more than one year for violating this law, the company law, the banking law, the insurance law, the financial holding company law, the business accounting law, or for fraud, breach of trust, embezzlement, forgery of documents, or for business crimes. However, this restriction shall not apply if three years have elapsed after the completion of execution, the expiration of probation or pardon. 2. Circumstances in which a party to a transaction may not be a related party or have a material relationship with the transaction party. 3. If the company should obtain the appraisal reports of two or more professional appraisers, appraisers of different specialties or appraisers shall not be related to each other or have substantial relationship with each other. <p>When issuing a valuation report or opinion, the personnel referred to in the preceding paragraph shall comply with the following matters:</p> <ol style="list-style-type: none"> 1. Before undertaking a case, you should carefully evaluate your professional ability, practical experience and independence. 2. When examining a case, it is necessary to properly plan and implement the appropriate operation process to form a conclusion and issue a report or opinion based on it; The procedures, information and conclusions collected will be detailed in the case working paper. 3. The integrity, correctness and rationality of the data sources, parameters and information used shall be evaluated item by item as the basis for issuing the valuation report or opinion. 4. The declaration shall include the professionalism and independence of relevant personnel, the reasonableness and correctness of the information used in the evaluation, and compliance with relevant laws and regulations. 	<p>Revise with the actual operation of the company</p>
<p>Article 7: the limit on the acquisition of real estate and its right to use assets or securities not for business use The limits for the company and its subsidiaries to individually acquire real estate and its right to use assets or securities not for business use are as follows:</p> <ol style="list-style-type: none"> 1. The total investment of real estate and its right to use assets not for business use shall not be higher than 50% of the net value of the company's financial 	<p>Article 7: the limit on the acquisition of real estate and its right to use assets or securities not for business use</p> <ol style="list-style-type: none"> 1. The limits for the company to acquire real estate and its right to use assets or securities not for business use are as follows: <ol style="list-style-type: none"> (1) The total assets of real estate purchased for non business use and its use right shall not exceed 40% of the paid in capital of the company. 	<p>Revise with the actual operation of the company</p>

Amendment	Current Articles	Explanation
<p>statements audited, certified or reviewed by a CPA in the most recent period.</p> <p>2. The total amount invested in securities shall not be higher than the net value of the company's financial statements audited, certified or reviewed by a CPA in the most recent period.</p> <p>3. The amount invested in individual securities shall not be higher than the net value of the company's financial statements audited, certified or reviewed by a CPA in the most recent period.</p> <p>4. The limit on the amount of individual securities in the third paragraph of the preceding paragraph shall not apply to strategic investment cases.</p>	<p>(2) The total amount invested in securities shall not exceed 80% of the company's paid in capital or the net value of the latest financial statements, whichever is higher.</p> <p>(3) The amount invested in individual securities shall not exceed 50% of the company's paid in capital or the net value of the latest financial statements, whichever is higher.</p> <p>2. The limits for subsidiaries of the company to acquire real estate and its right to use assets or securities not for business use are as follows:</p> <p>(1) The total assets of real estate purchased for non business use and its use right shall not exceed 20% of the paid in capital of each subsidiary.</p> <p>(2) The total amount invested in securities shall not exceed the paid in capital of each subsidiary or the net value of the latest financial statements, whichever is higher.</p> <p>(3) The amount invested in individual securities shall not exceed the paid in capital of each subsidiary or the net value of the latest financial statements, whichever is higher.</p>	
<p>Article 8: evaluation and operating procedures for acquisition or disposal of securities</p> <p>1. Price determination method and reference basis To acquire or dispose of securities, the financial statements of the target company in the most recent period audited, certified or reviewed by a CPA shall be taken as a reference for evaluating the transaction price before the date of occurrence:</p> <p>(1) The acquisition or disposal of securities that have been traded on the centralized trading market or on the over-the-counter market of securities firms shall be determined according to the current market price.</p> <p>(2) When acquiring or disposing of securities that are not traded on the centralized trading market or on the over-the-counter business of securities firms, consideration shall be given to their net worth per share, profitability, future development potential, market interest rate, bond coupon rate, debtor's debt credit and negotiated with reference to the current trading price.</p> <p>2. Experts are invited to give opinions If the trading amount of securities acquired or disposed of reaches 20% of the company's paid in capital or NT \$300 million or more, a CPA shall be contacted to express an opinion on the rationality of the trading price before the date of occurrence. However, this restriction shall not apply if the securities have a public quotation in a flexible market or if otherwise prescribed by the FSC.</p> <p>3. Procedures for determining trading conditions and authorization limits</p> <p>(1) The trading of securities on the centralized trading market or the business premises of securities firms shall be determined by the responsible unit</p>	<p>Article 8: evaluation and operating procedures for acquisition or disposal of securities</p> <p>1. Price determination method and reference basis To acquire or dispose of securities, the financial statements of the target company in the most recent period audited, certified or reviewed by a CPA shall be taken as a reference for evaluating the transaction price before the date of occurrence:</p> <p>(1) The acquisition or disposal of securities that have been traded on the centralized trading market or on the over-the-counter market of securities firms shall be determined according to the current market price.</p> <p>(2) When acquiring or disposing of securities that are not traded on the centralized trading market or on the over-the-counter business of securities firms, consideration shall be given to their net worth per share, profitability, future development potential, market interest rate, bond coupon rate, debtor's debt credit and negotiated with reference to the current trading price.</p> <p>2. Experts are invited to give opinions Where securities are acquired or disposed of, and the transaction amount reaches 20% of the company's paid in capital or NT \$300 million or more, a CPA shall be contacted to express an opinion on the reasonableness of the transaction price before the date of occurrence. If the CPA needs to adopt an expert report, it shall be handled in accordance with the statement of Auditing Standards No. 20 issued by the accounting research and development foundation of the Republic of China (hereinafter referred to as the accounting research and Development Foundation). However, this restriction shall not apply if the securities have a public quotation in a flexible market or if otherwise prescribed by the</p>	<p>Revise with the actual operation of the company</p>

Amendment	Current Articles	Explanation
<p>according to the market conditions. Where the amount of each transaction is less than NT \$60 million (inclusive), the board of directors shall authorize the chairman of the board of directors to handle it with full power, and then submit it to the board of directors for ratification; If the transaction amount exceeds NT \$60 million, it shall be submitted to the board of directors for approval. Derivatives shall be handled in accordance with Article 8 of these procedures.</p> <p>(2) For securities trading that is not conducted on the centralized trading market or on the business premises of securities firms, in addition to the original share subscription (including the establishment of share subscription and cash capital increase subscription of a start-up company), the latest financial statements of the target company audited, certified or reviewed by a CPA shall be taken as a reference for evaluating the trading price, and its net worth per share, profitability and future development potential shall be considered. Where the amount of each transaction is less than NT \$100 million, The board of directors shall authorize the chairman of the board of directors to handle it with full power, and then report to the board of directors for ratification; If the transaction amount is more than NT \$100 million (inclusive), it shall be submitted to the board of directors for approval.</p> <p>(3) For the evaluation of various investments, each authority and responsible unit shall prepare and submit an evaluation report on the reasons for the proposed acquisition or disposal, the trading object, the trading price, the terms of receipt and payment, and the results of price evaluation before entering into a sales contract.</p> <p>4.~5. (omitted)</p>	<p>FSC.</p> <p>3. Authorization limit and level The acquisition or disposal of securities with a trading amount of less than NT \$50 million (inclusive) shall be reviewed and decided level by level according to the division of review authority; If the transaction amount exceeds NT \$50 million, it shall be approved by the audit committee and approved by the board of directors.</p> <p>4.~5. (omitted)</p>	
<p>Article 9: evaluation and operation procedures for acquisition or disposal of real estate, equipment or its use right assets</p> <p>1. Price determination method and reference basis The acquisition or disposal of real estate, equipment or its use right assets shall be signed and explained by the original user unit or relevant authority and responsibility unit, and the asset management unit shall choose one by means of price comparison, negotiation or bidding with reference to the announced present value, assessed value, actual transaction price of adjacent real estate, recent transaction price of similar assets, etc.</p> <p>2. Experts are invited to issue a valuation report For the acquisition or disposal of real estate, equipment or its right to use assets, in addition to the transaction with domestic government agencies, self commissioned construction, land rental commissioned construction, or the acquisition or disposal of equipment or its right to use assets for business use, if the transaction amount reaches 20% of the company's</p>	<p>Article 9: evaluation and operation procedures for acquisition or disposal of real estate, equipment or its use right assets</p> <p>1. Price determination method and reference basis The acquisition or disposal of real estate, equipment or its use right assets shall be signed and explained by the original user unit or relevant authority and responsibility unit, and the asset management unit shall choose one by means of price comparison, negotiation or bidding with reference to the announced present value, assessed value, actual transaction price of adjacent real estate, recent transaction price of similar assets, etc.</p> <p>2. Experts are invited to issue a valuation report For the acquisition or disposal of real estate, equipment or its right to use assets, in addition to the transaction with domestic government agencies, self commissioned construction, land rental commissioned construction, or the acquisition or disposal of equipment or its right to use assets for business use, if the transaction amount reaches 20% of the company's</p>	<p>Revise with the actual operation of the company</p>

Amendment	Current Articles	Explanation
<p>paid in capital or more than NT \$300 million, a valuation report issued by a professional appraiser shall be obtained before the date of occurrence, and the following provisions shall be met:</p> <p>(1) If a limited price, specific price or special price must be used as the reference basis of the transaction price for special reasons, the transaction shall be submitted to the Audit Committee for approval and the resolution of the board of directors; The same applies to subsequent changes in trading conditions.</p> <p>(2) If the transaction amount reaches NT \$1 billion or more, it shall be appraised by two or more professional appraisers.</p> <p>(3) If the appraisal result of a professional appraiser is under any of the following circumstances, except that the appraisal result of the acquired assets is higher than the transaction amount, or the appraisal result of the disposal of assets is lower than the transaction amount, it shall contact a CPA to express specific opinions on the reasons for the difference and the appropriateness of the transaction price:</p> <ol style="list-style-type: none"> 1. The difference between the valuation result and the transaction amount is more than 20% of the transaction amount. 2. The difference between the valuation results of two or more professional appraisers is more than 10% of the transaction amount. <p>(4) For professional appraisers, the date of issuance of the report and the date of establishment of the contract shall not exceed three months. However, if the current value announced in the same period is applicable and less than six months have elapsed, the original professional appraiser may issue an opinion.</p> <p>3. Procedures for determining trading conditions and authorization limits</p> <p>(1) When acquiring or disposing of real estate, the trading conditions and prices shall be determined with reference to the announced present value, assessed value and the actual trading price of adjacent real estate, and an analysis report shall be made, which shall be handled in accordance with the provisions of the authorization measures. If the trading amount is less than NT \$60 million (inclusive), the chairman of the board of directors shall be authorized to handle it with full power, and then submit it to the board of directors for ratification; If the transaction amount is more than NT \$60 million, it shall be submitted to the chairman for approval and approved by the board of directors.</p> <p>(2) The acquisition or disposal of other fixed assets shall be made by inquiry, price comparison, negotiation or bidding, and shall be handled in accordance with the authorization regulations. If the transaction amount is less than NT \$60 million (inclusive), the board of directors shall authorize</p>	<p>paid in capital or more than NT \$300 million, a valuation report issued by a professional appraiser shall be obtained before the date of occurrence, and the following provisions shall be met:</p> <p>(1) If a limited price, specific price or special price must be used as the reference basis of the transaction price for special reasons, the transaction shall be submitted to the Audit Committee for approval and the resolution of the board of directors; The same applies to subsequent changes in trading conditions.</p> <p>(2) If the transaction amount reaches NT \$1 billion or more, it shall be appraised by two or more professional appraisers.</p> <p>(3) Under any of the following circumstances, except that the valuation results of the assets obtained are higher than the transaction amount, or the valuation results of the assets disposed of are lower than the transaction amount, a professional appraiser shall contact a CPA to handle it in accordance with the provisions of the bulletin of Auditing Standards No. 20 issued by the accounting research and development foundation, and express specific opinions on the reasons for the differences and the appropriateness of the transaction price:</p> <ol style="list-style-type: none"> 1. The difference between the valuation result and the transaction amount is more than 20% of the transaction amount. 2. The difference between the valuation results of two or more professional appraisers is more than 10% of the transaction amount. <p>(4) For professional appraisers, the date of issuance of the report and the date of establishment of the contract shall not exceed three months. However, if the current value announced in the same period is applicable and less than six months have elapsed, the original professional appraiser may issue an opinion.</p> <p>If the assets are acquired or disposed of through the auction procedure of the court, the certification file issued by the court may replace the valuation report.</p> <p>3. Authorization limit and level The acquisition or disposal of real estate, equipment or its use right assets with a transaction amount of less than NT \$50 million (inclusive) shall be reviewed and decided level by level according to the review authority division table; If the transaction amount exceeds NT \$50 million, it shall be approved by the audit committee and approved by the board of directors.</p> <p>4.~5. (omitted)</p>	

Amendment	Current Articles	Explanation
<p>the chairman of the board of directors to handle it with full power, and then submit it to the board of directors for ratification; If the transaction amount is more than NT \$60 million, it shall be submitted to the chairman for approval and approved by the board of directors.</p> <p>(3) For the appraisal of real estate or other fixed assets, the competent and responsible units shall prepare and submit an appraisal report on the reasons for the proposed acquisition or disposal, the trading object, the trading price, the terms of payment and collection, and the results of price appraisal before entering into a sales contract.</p> <p>4.~5. (omitted)</p>		
<p>Article 10: evaluation and operating procedures for the acquisition or disposal of intangible assets or their right to use assets or membership cards</p> <p>1. Price determination method and reference basis When acquiring or disposing of intangible assets or their right to use assets or membership cards, consideration shall be given to the possible benefits and fair market value of the assets in the future. If necessary, it shall be negotiated with the counterparty with reference to expert opinions.</p> <p>2. Experts are invited to give opinions</p> <p>(1) If a member certificate is obtained or disposed of, and the transaction amount reaches 1% of the company's paid in capital or more than NT \$1 million, an expert shall be contacted to issue a price evaluation report before the date of occurrence.</p> <p>(2) If the acquisition or disposal of intangible assets or their right to use assets has a transaction amount of 10% of the company's paid in capital or more than NT \$50 million, an expert shall be contacted to issue a valuation report before the date of occurrence.</p> <p>(3) Where an enterprise obtains or disposes of intangible assets or its right to use assets or membership certificates, and the transaction amount reaches 20% of the company's paid in capital or NT \$300 million or more, in addition to trading with domestic government agencies, it shall contact a CPA to express its opinion on the rationality of the transaction price before the date of occurrence of the fact.</p> <p>Three to five (omitted)</p>	<p>Article 11: evaluation and operating procedures for the acquisition or disposal of intangible assets or their right to use assets or membership cards</p> <p>1. Price determination method and reference basis When acquiring or disposing of intangible assets or their right to use assets or membership cards, consideration shall be given to the possible benefits and fair market value of the assets in the future. If necessary, it shall be negotiated with the counterparty with reference to expert opinions.</p> <p>2. Experts are invited to give opinions</p> <p>(1) If a member certificate is obtained or disposed of, and the transaction amount reaches 1% of the company's paid in capital or more than NT \$1 million, an expert shall be contacted to issue a price evaluation report before the date of occurrence.</p> <p>(2) If the acquisition or disposal of intangible assets or their right to use assets has a transaction amount of 10% of the company's paid in capital or more than NT \$50 million, an expert shall be contacted to issue a valuation report before the date of occurrence.</p> <p>(3) Where an enterprise obtains or disposes of intangible assets or its right to use assets or membership certificates, and the transaction amount reaches 20% of the company's paid in capital or NT \$300 million or more, it shall, in addition to trading with domestic government agencies, consult a CPA to express its opinion on the rationality of the transaction price before the date of occurrence of the fact, and the CPA shall handle it in accordance with the provisions of the bulletin of Auditing Standards No. 20 issued by the accounting research and development foundation.</p> <p>Three to five (omitted)</p>	<p>Revise with the actual operation of the company</p>
<p>Article 11: the calculation of the transaction amount in the preceding three articles shall be carried out in accordance with the provisions of paragraph 1 of Article 15, and the said one-year period is calculated retroactively for one year based on the date of the</p>	<p>Article 11-1: the calculation of the transaction amount in the preceding four articles shall be carried out in accordance with the provisions of paragraph 1 of Article 15, and the said one-year period is calculated retroactively for one year based on the date of the occurrence of the current</p>	<p>Revise with the actual operation of the company</p>

Amendment	Current Articles	Explanation
<p>occurrence of the current transaction fact. The part of the valuation report or the opinion of the accountant issued by the person who has obtained the professional valuation in accordance with the provisions shall be exempted from re inclusion.</p> <p>If the assets are acquired or disposed of through the auction procedure of the court, the certification file issued by the court may replace the valuation report.</p>	<p>transaction. The part of the valuation report or CPA's opinion issued by the person who has obtained professional valuation in accordance with the regulations shall be exempted from re inclusion. The first paragraph of Article 10 has been submitted to the Audit Committee for approval and approved by the board of directors in accordance with the regulations, and the part is exempted from re counting.</p>	
<p>Original article 12 deleted</p>	<p>Article 12: evaluation and operating procedures for obtaining or disposing of the creditor's rights of financial institutions In principle, this corporation will not engage in the transaction of acquiring or disposing of the creditor's rights of financial institutions. If it wants to engage in the transaction of acquiring or disposing of the creditor's rights of financial institutions later, it will submit it to the board of directors for approval before formulating the relevant evaluation and operating procedures.</p>	<p>Revise with the actual operation of the company</p>
<p>Article 12: evaluation and operating procedures for related party transactions When the company acquires or disposes of assets with its related parties, in addition to handling the relevant resolution procedures and assessing the reasonableness of trading conditions in accordance with Articles 8, 9, 10 and 11 and this article, if the transaction amount reaches more than 10% of the company's total assets, it shall also obtain the valuation report or CPA's opinion issued by the professional appraiser in accordance with Articles 8, 9, 10 and 11. In addition, when judging whether the trading partner is a related person, in addition to paying attention to its legal form, we should also consider the substantive relationship.</p> <p>1. Acquisition or disposal of real estate or its right to use assets from a related person, or acquisition or disposal of other assets other than real estate or its right to use assets with a related person, and the transaction amount reaches 20% of the company's paid in capital, 10% of its total assets, or NT \$300 million or more, except for the purchase and sale of domestic government bonds, bonds with repurchase and repurchase conditions, and the purchase or repurchase of money market funds issued by domestic securities investment trust enterprises, The following information shall be submitted to the Audit Committee for approval and the board of directors for approval before signing the transaction contract and making payment:</p> <p>(1) The purpose, necessity and expected benefits of the acquisition or disposal of assets.</p> <p>(2) The reason for selecting the related party as the trading partner.</p> <p>(3) Information related to the evaluation of the reasonableness of the scheduled trading conditions in accordance with subparagraphs 2 and 3 of paragraph 1 of this article when acquiring real estate or its use right assets from related parties.</p> <p>(4) The original acquisition date and price of the</p>	<p>Article 10: evaluation and operating procedures for related party transactions When acquiring or disposing of assets between this corporation and its related parties, in addition to handling the relevant resolution procedures and evaluating the rationality of trading conditions in accordance with the provisions of the preceding article and the following provisions, if the trading amount reaches 10% or more of the total assets of the company, it shall also obtain the valuation report or CPA opinion issued by a professional appraiser in accordance with the provisions of the preceding article. In addition, when judging whether the trading partner is a related person, in addition to paying attention to its legal form, we should also consider the substantive relationship.</p> <p>1. Acquisition or disposal of real estate or its right to use assets from a related person, or acquisition or disposal of other assets other than real estate or its right to use assets with a related person, and the transaction amount reaches 20% of the company's paid in capital, 10% of its total assets, or NT \$300 million or more, except for the purchase and sale of domestic government bonds, bonds with repurchase and repurchase conditions, and the purchase or repurchase of money market funds issued by domestic securities investment trust enterprises, The following information shall be submitted to the Audit Committee for approval and the board of directors for approval before signing the transaction contract and making payment:</p> <p>(1) The purpose, necessity and expected benefits of the acquisition or disposal of assets.</p> <p>(2) The reason for selecting the related party as the trading partner.</p> <p>(3) Information related to the evaluation of the reasonableness of the scheduled trading conditions in accordance with subparagraphs 2 and 3 of paragraph 1 of this article when acquiring real estate or its use right assets from related parties.</p>	<p>Revise with the actual operation of the company</p>

Amendment	Current Articles	Explanation
<p>related party, the trading partner and its relationship with the company and the related party.</p> <p>(5) It is expected that the cash income and expenditure forecast statement of each month in the coming year from the beginning of the contracting month, and evaluate the necessity of the transaction and the rationality of the use of funds.</p> <p>(6) The appraisal report issued by the professional appraiser obtained, or the opinion of the accountant.</p> <p>(7) Restrictions on this transaction and other important agreements.</p> <p>The board of directors may authorize the chairman of the board of directors to make a decision in advance within a certain amount between the company and the parent company, subsidiaries, or subsidiaries that directly or indirectly hold 100% of the issued shares or total capital to acquire or dispose of equipment for business use or its use right assets and real estate use right assets, and then submit it to the board of directors of the latest period for ratification.</p> <p>Where an audit committee has been established in accordance with the provisions of this law, the matters that shall be recognized by the supervisor in accordance with paragraph 1 shall first be approved by more than half of all the members of the audit committee and submitted to the board of directors for resolution.</p> <p>Where a public company or its subsidiary that is not a domestic public company has a transaction referred to in paragraph 1 and the transaction amount reaches 10% or more of the total assets of the public company, the public company shall submit the information listed in paragraph 1 to the shareholders' meeting for approval before signing a transaction contract and making payment. However, this restriction does not apply to transactions between a public company and its parent company, subsidiaries, or its subsidiaries.</p> <p>The calculation of the transaction amount referred to in paragraph 1 and the preceding paragraph shall be conducted in accordance with paragraph 2 of Article 15, and the said one-year period is calculated retroactively one year based on the date of the occurrence of the current transaction, and the part that has been submitted to the shareholders' meeting, the board of directors for approval and the supervisor for recognition in accordance with these standards shall be exempted from re counting.</p> <p>2.~5. (omitted)</p>	<p>(4) The original acquisition date and price of the related party, the trading partner and its relationship with the company and the related party.</p> <p>(5) It is expected that the cash income and expenditure forecast statement of each month in the coming year from the beginning of the contracting month, and evaluate the necessity of the transaction and the rationality of the use of funds.</p> <p>(6) The appraisal report issued by the professional appraiser obtained, or the opinion of the accountant.</p> <p>(7) Restrictions on this transaction and other important agreements.</p> <p>The board of directors may authorize the chairman of the board of directors to make a decision in advance within a certain amount between the company and the parent company, subsidiaries, or subsidiaries that directly or indirectly hold 100% of the issued shares or total capital to acquire or dispose of equipment for business use or its use right assets and real estate use right assets, and then submit it to the board of directors of the latest period for ratification.</p>	
<p>Article 15: Announcement and declaration procedures</p> <p>1. Where this corporation acquires or disposes of assets under the following circumstances, it shall, according to the nature and in the prescribed format, announce and report the relevant information on the website designated by the FSC within two days from the date</p>	<p>Article 15: Announcement and declaration procedures</p> <p>1. Where this corporation acquires or disposes of assets under the following circumstances, it shall, according to the nature and in the prescribed format, announce and report the relevant information on the website designated by the FSC within two days from the date</p>	<p>Revise with the actual operation of the company</p>

Amendment	Current Articles	Explanation
<p>of occurrence:</p> <p>(1) Acquire or dispose of real estate or its use right assets from related parties, or acquire or dispose of other assets other than real estate or its use right assets with related parties, and the transaction amount reaches 20% of the company's paid in capital, 10% of the total assets or more than NT \$300 million. However, this restriction shall not apply to the purchase and sale of domestic government bonds, bonds with buy back or sell back conditions, or the subscription or repurchase of money market funds issued by domestic securities investment trust enterprises.</p> <p>(2) Merger, division, acquisition or transfer of shares.</p> <p>(3) Losses from derivatives trading reach the maximum amount of all or individual contract losses specified in the prescribed handling procedures.</p> <p>(4) The type of assets acquired or disposed of is equipment for business use or its use right assets, and the trading partner is not a related party, and the trading amount reaches one of the following provisions:</p> <p>(1) A public company with a paid in capital of NT \$10 billion has a transaction amount of more than NT \$500 million.</p> <p>(2) A public company with a paid in capital of more than NT \$10 billion has a transaction amount of more than NT \$1 billion.</p> <p>(5) The company expects to invest more than NT \$500 million in the transaction of real estate acquired by means of self owned land contracting, land leasing, joint construction and house distribution, joint construction and sharing, joint construction and sub sale, and its trading partner is not a related party.</p> <p>(6) Asset transactions other than those in the preceding six subparagraphs, the disposal of creditor's rights by financial institutions or investment in the mainland, and the transaction amount reaches 20% of the company's paid in capital or more than NT \$300 million. However, the following circumstances shall not apply:</p> <ol style="list-style-type: none"> 1. Trading of domestic government bonds or foreign government bonds with a credit rating not lower than the sovereign rating of China. 2. Those who specialize in investment, buy and sell securities on the stock exchange or the business premises of securities firms, or subscribe for foreign government bonds or ordinary corporate bonds and general financial bonds (excluding subordinated bonds) not involving equity issued in the primary market, or subscribe for or buy back securities investment trust funds or futures trust funds, or subscribe for or sell back index investment securities, or securities firms need to Act as a consultant for emerging stock companies recommending securities firms to subscribe for 	<p>of occurrence:</p> <p>(1) Acquire or dispose of real estate or its use right assets from related parties, or acquire or dispose of other assets other than real estate or its use right assets with related parties, and the transaction amount reaches 20% of the company's paid in capital, 10% of the total assets or more than NT \$300 million. However, this restriction shall not apply to the purchase and sale of domestic government bonds, bonds with buy back or sell back conditions, or the subscription or repurchase of money market funds issued by domestic securities investment trust enterprises.</p> <p>(2) Merger, division, acquisition or transfer of shares.</p> <p>(3) Losses from derivatives trading reach the maximum amount of all or individual contract losses specified in the prescribed handling procedures.</p> <p>(4) The type of assets acquired or disposed of is equipment for business use or its use right assets, and the trading partner is not a related party, and the trading amount reaches one of the following provisions:</p> <p>(1) A public company with a paid in capital of NT \$10 billion has a transaction amount of more than NT \$500 million.</p> <p>(2) A public company with a paid in capital of more than NT \$10 billion has a transaction amount of more than NT \$1 billion.</p> <p>(5) The company expects to invest more than NT \$500 million in the transaction of real estate acquired by means of self owned land contracting, land leasing, joint construction and house distribution, joint construction and sharing, joint construction and sub sale, and its trading partner is not a related party.</p> <p>(6) Asset transactions other than those in the preceding six subparagraphs, the disposal of creditor's rights by financial institutions or investment in the mainland, and the transaction amount reaches 20% of the company's paid in capital or more than NT \$300 million. However, the following circumstances shall not apply:</p> <ol style="list-style-type: none"> 1. Buying and selling domestic government bonds. 2. Those who specialize in investment, buy and sell securities on the stock exchange or the business premises of securities firms, subscribe for ordinary corporate bonds and general financial bonds (excluding subordinated bonds) not involving equity raised and issued on the primary market, or subscribe for or buy back securities investment trust funds or futures trust funds, or securities firms for underwriting business needs Act as a consultant for emerging stock companies recommending securities firms to subscribe for securities in accordance with the regulations of the ROC OTC market. 3. To buy and sell bonds subject to buy back or sell back conditions, and to subscribe for or buy 	

Amendment	Current Articles	Explanation
<p>securities in accordance with the regulations of the ROC OTC market.</p> <p>3. To buy and sell bonds subject to buy back or sell back conditions, and to subscribe for or buy back money market funds issued by domestic securities investment trust enterprises.</p> <p>The aforesaid transaction amount shall be calculated according to the following methods:</p> <p>(1) Amount of each transaction.</p> <p>(2) Accumulated amount of transactions with the same nature acquired or disposed of by the same counterparty within one year.</p> <p>(3) The accumulated amount of real estate acquired or disposed of in the same year.</p> <p>(4) The cumulative amount of the same securities acquired or disposed of (acquired and disposed of separately) within one year.</p> <p>The term "within one year" referred to in the preceding paragraph is calculated retroactively for one year based on the date of the occurrence of the current transaction, and the part that has been announced in accordance with the regulations is exempted from re counting.</p> <p>2.~5. (omitted)</p>	<p>back money market funds issued by domestic securities investment trust enterprises.</p> <p>The aforesaid transaction amount shall be calculated according to the following methods:</p> <p>(1) Amount of each transaction.</p> <p>(2) Accumulated amount of transactions with the same nature acquired or disposed of by the same counterparty within one year.</p> <p>(3) The accumulated amount of real estate acquired or disposed of in the same year.</p> <p>(4) The cumulative amount of the same securities acquired or disposed of (acquired and disposed of separately) within one year.</p> <p>The term "within one year" referred to in the preceding paragraph is calculated retroactively for one year based on the date of the occurrence of the current transaction, and the part that has been announced in accordance with the regulations is exempted from re counting.</p> <p>2.~5. (omitted)</p>	
<p>Article 20:</p> <p>These procedures were concluded on May 2, 2000.</p> <p>The first amendment was made on June 2, 2002</p> <p>The second amendment was made on May 3, 2003.</p> <p>The third amendment was made on June 28, 2010.</p> <p>The fourth revision was made on June 7, 2012.</p> <p>The fifth amendment was made on June 16, 2014.</p> <p>The sixth amendment was made on June 26, 2017.</p> <p>The Seventh Amendment was made on June 26,2019.</p> <p>The eighth amendment was made on June 29, 2020.</p> <p>The Ninth Amendment was made on June 21, 2022.</p>	<p>Article 20:</p> <p>These procedures were concluded on May 2, 2000.</p> <p>The first amendment was made on June 2, 2002</p> <p>The second amendment was made on May 3, 2003.</p> <p>The third amendment was made on June 28, 2010.</p> <p>The fourth revision was made on June 7, 2012.</p> <p>The fifth amendment was made on June 16, 2014.</p> <p>The sixth amendment was made on June 26, 2017.</p> <p>The Seventh Amendment was made on June 26, 2019.</p> <p>The eighth amendment was made on June 29, 2020.</p>	<p>Added the amendment date.</p>

List of Director Candidates

姓 名	學 歷	經 歷	現 職
大江生醫 股份有限公司 法人董事代表人 邱琮傑	成功大學化學工程 學系所碩士	財團法人食品工業發展研究 所副研究員	大江生醫股份有限公司 客戶成功經理
台塑生醫科技 股份有限公司 法人董事代表人 賴世明	美國奧勒岡州波特 蘭大學MBA	台塑企業總管理處總經理室 台塑企業總管理處採購部 台塑鋁鐵材料股份有限公司	台塑企業總管理處醫學 事業發展中心副組長

Waiver of Non-Compete Clause for Directors

姓 名	解 除 競 業 禁 止
大江生醫股份有 限公司 法人董事代表人 邱琮傑	大江生醫股份有限公司客戶成功經理
台塑生醫科技股 份有限公司 法人董事代表人 賴世明	台塑企業總管理處醫學事業發展中心副組長